Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 31 | 2023 | 1630 | 3.120 |
Why?
|
| Alzheimer Disease | 32 | 2024 | 2005 | 3.110 |
Why?
|
| Cognitive Dysfunction | 17 | 2024 | 969 | 2.250 |
Why?
|
| Hospitalization | 5 | 2019 | 319 | 1.750 |
Why?
|
| Dementia | 11 | 2024 | 527 | 1.650 |
Why?
|
| Cognition | 20 | 2023 | 1314 | 1.630 |
Why?
|
| Aged, 80 and over | 54 | 2024 | 4930 | 1.570 |
Why?
|
| Health Literacy | 7 | 2018 | 105 | 1.510 |
Why?
|
| Independent Living | 12 | 2022 | 285 | 1.370 |
Why?
|
| Aged | 60 | 2024 | 9618 | 1.270 |
Why?
|
| Activities of Daily Living | 10 | 2022 | 506 | 1.110 |
Why?
|
| Female | 62 | 2023 | 16402 | 1.100 |
Why?
|
| Male | 63 | 2023 | 15844 | 1.080 |
Why?
|
| Cohort Studies | 20 | 2022 | 1952 | 0.930 |
Why?
|
| Humans | 77 | 2024 | 29801 | 0.920 |
Why?
|
| Decision Making | 12 | 2016 | 227 | 0.900 |
Why?
|
| Brain | 15 | 2022 | 1726 | 0.890 |
Why?
|
| Economics | 3 | 2018 | 18 | 0.860 |
Why?
|
| Longitudinal Studies | 18 | 2023 | 1462 | 0.760 |
Why?
|
| DNA-Binding Proteins | 5 | 2022 | 263 | 0.760 |
Why?
|
| Work | 1 | 2020 | 10 | 0.740 |
Why?
|
| Women | 1 | 2020 | 14 | 0.740 |
Why?
|
| Social Behavior | 2 | 2011 | 99 | 0.720 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2021 | 105 | 0.660 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2019 | 18 | 0.650 |
Why?
|
| Emergencies | 1 | 2019 | 39 | 0.640 |
Why?
|
| Social Participation | 2 | 2022 | 11 | 0.580 |
Why?
|
| Cognition Disorders | 6 | 2016 | 1032 | 0.570 |
Why?
|
| Interpersonal Relations | 3 | 2014 | 105 | 0.570 |
Why?
|
| Information Literacy | 2 | 2014 | 9 | 0.560 |
Why?
|
| Neuropsychological Tests | 15 | 2021 | 1270 | 0.560 |
Why?
|
| Biomarkers | 2 | 2020 | 704 | 0.540 |
Why?
|
| Social Environment | 3 | 2011 | 81 | 0.540 |
Why?
|
| Risk Assessment | 1 | 2019 | 683 | 0.520 |
Why?
|
| United States | 9 | 2024 | 2344 | 0.510 |
Why?
|
| Motor Activity | 3 | 2013 | 372 | 0.490 |
Why?
|
| Delay Discounting | 1 | 2015 | 26 | 0.490 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 54 | 0.480 |
Why?
|
| Caregivers | 10 | 2008 | 144 | 0.470 |
Why?
|
| Trust | 1 | 2014 | 16 | 0.460 |
Why?
|
| Fraud | 1 | 2014 | 23 | 0.460 |
Why?
|
| Mental Health | 2 | 2014 | 105 | 0.430 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 194 | 0.430 |
Why?
|
| Age Factors | 8 | 2020 | 852 | 0.420 |
Why?
|
| Medicare | 4 | 2024 | 123 | 0.410 |
Why?
|
| Educational Status | 6 | 2020 | 297 | 0.400 |
Why?
|
| Association | 1 | 2011 | 8 | 0.400 |
Why?
|
| Residence Characteristics | 6 | 2016 | 216 | 0.380 |
Why?
|
| Diet, Mediterranean | 2 | 2023 | 64 | 0.380 |
Why?
|
| Lewy Body Disease | 1 | 2012 | 100 | 0.380 |
Why?
|
| Mobility Limitation | 2 | 2012 | 97 | 0.380 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 154 | 0.380 |
Why?
|
| Risk Factors | 11 | 2022 | 2465 | 0.360 |
Why?
|
| Risk | 4 | 2015 | 216 | 0.350 |
Why?
|
| Loneliness | 3 | 2023 | 55 | 0.330 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 1859 | 0.310 |
Why?
|
| Middle Aged | 20 | 2019 | 9952 | 0.310 |
Why?
|
| Memory | 6 | 2018 | 323 | 0.300 |
Why?
|
| Prospective Studies | 6 | 2019 | 1821 | 0.300 |
Why?
|
| Apolipoprotein E4 | 4 | 2022 | 233 | 0.300 |
Why?
|
| Autopsy | 5 | 2021 | 338 | 0.290 |
Why?
|
| Sex Factors | 7 | 2020 | 497 | 0.290 |
Why?
|
| Brain Infarction | 2 | 2018 | 74 | 0.280 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 346 | 0.280 |
Why?
|
| Quality of Life | 3 | 2012 | 676 | 0.260 |
Why?
|
| Apolipoproteins E | 4 | 2023 | 235 | 0.260 |
Why?
|
| Mental Competency | 4 | 2008 | 8 | 0.260 |
Why?
|
| Social Isolation | 2 | 2023 | 23 | 0.250 |
Why?
|
| Chicago | 7 | 2021 | 867 | 0.250 |
Why?
|
| Mental Status and Dementia Tests | 3 | 2020 | 81 | 0.240 |
Why?
|
| Income | 3 | 2022 | 77 | 0.230 |
Why?
|
| Genotype | 2 | 2018 | 399 | 0.230 |
Why?
|
| Family | 2 | 2020 | 93 | 0.230 |
Why?
|
| Stress, Psychological | 3 | 2016 | 249 | 0.210 |
Why?
|
| Neuroimaging | 2 | 2021 | 138 | 0.210 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2016 | 351 | 0.200 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 26 | 0.200 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 143 | 0.190 |
Why?
|
| Patient Participation | 4 | 2008 | 51 | 0.190 |
Why?
|
| Politics | 3 | 2008 | 17 | 0.190 |
Why?
|
| Disease Progression | 4 | 2020 | 812 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 337 | 0.190 |
Why?
|
| Depression | 3 | 2015 | 472 | 0.180 |
Why?
|
| Financing, Personal | 3 | 2018 | 19 | 0.180 |
Why?
|
| Social Segregation | 1 | 2020 | 8 | 0.180 |
Why?
|
| Cognitive Reserve | 1 | 2021 | 38 | 0.180 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 970 | 0.180 |
Why?
|
| Employment | 1 | 2020 | 42 | 0.180 |
Why?
|
| Brain Diseases | 1 | 2021 | 83 | 0.180 |
Why?
|
| Personality | 1 | 2021 | 67 | 0.180 |
Why?
|
| Arteriolosclerosis | 2 | 2021 | 74 | 0.170 |
Why?
|
| Awareness | 1 | 2020 | 38 | 0.170 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 329 | 0.170 |
Why?
|
| Cognitive Aging | 1 | 2020 | 81 | 0.170 |
Why?
|
| Amyloid beta-Peptides | 4 | 2023 | 302 | 0.170 |
Why?
|
| Memory Disorders | 1 | 2020 | 177 | 0.170 |
Why?
|
| Prevalence | 3 | 2012 | 494 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 5 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 6 | 0.160 |
Why?
|
| Disability Evaluation | 2 | 2011 | 327 | 0.160 |
Why?
|
| Research Subjects | 2 | 2008 | 13 | 0.160 |
Why?
|
| Models, Neurological | 1 | 2018 | 32 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 45 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 433 | 0.160 |
Why?
|
| Neural Pathways | 1 | 2018 | 82 | 0.150 |
Why?
|
| Mutation | 1 | 2020 | 395 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2018 | 112 | 0.150 |
Why?
|
| Neurofibrillary Tangles | 4 | 2022 | 189 | 0.150 |
Why?
|
| Regression Analysis | 2 | 2015 | 298 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 2018 | 140 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 150 | 0.150 |
Why?
|
| Learning | 2 | 2016 | 80 | 0.150 |
Why?
|
| White Matter | 2 | 2016 | 150 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 474 | 0.140 |
Why?
|
| Informed Consent | 2 | 2008 | 19 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 139 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 78 | 0.140 |
Why?
|
| Sepsis | 1 | 2018 | 147 | 0.140 |
Why?
|
| RNA Splicing | 1 | 2016 | 11 | 0.140 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 13 | 0.140 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2016 | 14 | 0.130 |
Why?
|
| Intelligence | 1 | 2016 | 25 | 0.130 |
Why?
|
| Adult | 6 | 2022 | 8730 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 201 | 0.130 |
Why?
|
| Interview, Psychological | 2 | 2008 | 36 | 0.130 |
Why?
|
| Comprehension | 1 | 2016 | 28 | 0.130 |
Why?
|
| Incidence | 3 | 2016 | 759 | 0.130 |
Why?
|
| Gray Matter | 1 | 2016 | 56 | 0.130 |
Why?
|
| Alleles | 2 | 2018 | 216 | 0.130 |
Why?
|
| Crime Victims | 1 | 2016 | 25 | 0.130 |
Why?
|
| Amyloid | 3 | 2021 | 54 | 0.130 |
Why?
|
| Health Behavior | 2 | 2014 | 159 | 0.130 |
Why?
|
| Psychological Tests | 1 | 2015 | 52 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2017 | 508 | 0.120 |
Why?
|
| Time Factors | 3 | 2014 | 1640 | 0.120 |
Why?
|
| Multilingualism | 1 | 2014 | 11 | 0.120 |
Why?
|
| Minority Groups | 1 | 2015 | 67 | 0.120 |
Why?
|
| Racism | 1 | 2015 | 32 | 0.120 |
Why?
|
| Music | 1 | 2014 | 19 | 0.120 |
Why?
|
| Poverty | 1 | 2015 | 97 | 0.120 |
Why?
|
| tau Proteins | 3 | 2022 | 213 | 0.110 |
Why?
|
| Neoplasms | 1 | 2017 | 257 | 0.110 |
Why?
|
| Social Support | 2 | 2015 | 186 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 177 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2018 | 286 | 0.110 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 222 | 0.110 |
Why?
|
| Automobile Driving | 1 | 2012 | 12 | 0.100 |
Why?
|
| Neprilysin | 1 | 2012 | 9 | 0.100 |
Why?
|
| Actigraphy | 1 | 2012 | 98 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2013 | 129 | 0.100 |
Why?
|
| Lewy Bodies | 3 | 2018 | 198 | 0.100 |
Why?
|
| Muscle Strength | 1 | 2012 | 129 | 0.100 |
Why?
|
| Environmental Health | 1 | 2010 | 8 | 0.090 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 18 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 53 | 0.090 |
Why?
|
| Health Status | 2 | 2012 | 230 | 0.090 |
Why?
|
| Lead Poisoning, Nervous System, Adult | 1 | 2010 | 1 | 0.090 |
Why?
|
| Lead | 1 | 2010 | 3 | 0.090 |
Why?
|
| Phobic Disorders | 1 | 2010 | 65 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2010 | 25 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 2010 | 20 | 0.090 |
Why?
|
| Urban Population | 1 | 2011 | 143 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2005 | 1126 | 0.080 |
Why?
|
| Urban Health | 1 | 2008 | 23 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 425 | 0.080 |
Why?
|
| Third-Party Consent | 1 | 2008 | 1 | 0.080 |
Why?
|
| Ethics, Research | 1 | 2008 | 3 | 0.080 |
Why?
|
| Assisted Living Facilities | 1 | 2008 | 3 | 0.080 |
Why?
|
| Attitude | 1 | 2008 | 29 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1186 | 0.080 |
Why?
|
| Nursing Homes | 1 | 2008 | 38 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 54 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2015 | 156 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 64 | 0.070 |
Why?
|
| Selegiline | 1 | 2005 | 6 | 0.070 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 9 | 0.070 |
Why?
|
| Mood Disorders | 1 | 2005 | 29 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 640 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 40 | 0.060 |
Why?
|
| Self Report | 2 | 2016 | 221 | 0.060 |
Why?
|
| Civil Rights | 1 | 2004 | 3 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 411 | 0.060 |
Why?
|
| Illinois | 2 | 2015 | 241 | 0.060 |
Why?
|
| Statistics as Topic | 2 | 2015 | 114 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 16 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 32 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2022 | 8 | 0.050 |
Why?
|
| Infarction | 1 | 2022 | 25 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 7 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 24 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 68 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 1246 | 0.050 |
Why?
|
| Logistic Models | 2 | 2018 | 410 | 0.050 |
Why?
|
| Motor Skills | 1 | 2021 | 62 | 0.050 |
Why?
|
| Individuality | 1 | 2021 | 22 | 0.050 |
Why?
|
| Neuroticism | 1 | 2021 | 34 | 0.050 |
Why?
|
| Southeastern United States | 1 | 2020 | 9 | 0.050 |
Why?
|
| Midwestern United States | 1 | 2020 | 67 | 0.040 |
Why?
|
| Baltimore | 2 | 2011 | 14 | 0.040 |
Why?
|
| Religion | 1 | 2019 | 40 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 8 | 0.040 |
Why?
|
| Heterozygote | 1 | 2018 | 103 | 0.040 |
Why?
|
| Neuropathology | 1 | 2018 | 81 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 285 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2017 | 27 | 0.040 |
Why?
|
| Mental Status Schedule | 2 | 2008 | 114 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 320 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 24 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 85 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2017 | 146 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 60 | 0.030 |
Why?
|
| Critical Care | 1 | 2018 | 242 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 78 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2016 | 109 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 256 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 20 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 96 | 0.030 |
Why?
|
| Cities | 1 | 2015 | 14 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 78 | 0.030 |
Why?
|
| Financial Management | 1 | 2015 | 25 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 36 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 221 | 0.030 |
Why?
|
| Memory, Episodic | 1 | 2016 | 120 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 36 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 74 | 0.030 |
Why?
|
| Spouses | 2 | 2005 | 26 | 0.030 |
Why?
|
| Language | 1 | 2014 | 78 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 744 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 14 | 0.030 |
Why?
|
| Licensure | 1 | 2012 | 9 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2012 | 14 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 23 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 17 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 34 | 0.030 |
Why?
|
| Environment | 1 | 2012 | 47 | 0.030 |
Why?
|
| Transfection | 1 | 2012 | 128 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 98 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 1629 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 325 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 258 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 323 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 123 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 108 | 0.020 |
Why?
|
| Executive Function | 1 | 2011 | 124 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2010 | 46 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 107 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 264 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 220 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 376 | 0.020 |
Why?
|
| Intermittent Claudication | 1 | 2008 | 4 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2008 | 20 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 2008 | 20 | 0.020 |
Why?
|
| Simvastatin | 1 | 2008 | 6 | 0.020 |
Why?
|
| Social Class | 1 | 2008 | 65 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 120 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 119 | 0.020 |
Why?
|
| Health Surveys | 1 | 2008 | 96 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 140 | 0.020 |
Why?
|
| Tibia | 1 | 2010 | 266 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 874 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 4634 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3557 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2008 | 175 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 558 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 349 | 0.020 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 26 | 0.020 |
Why?
|
| Judgment | 1 | 2005 | 9 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2005 | 55 | 0.020 |
Why?
|
| Nootropic Agents | 1 | 2005 | 12 | 0.020 |
Why?
|
| Policy Making | 1 | 2004 | 15 | 0.020 |
Why?
|
| Stroke | 1 | 2008 | 294 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2004 | 56 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2005 | 165 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 147 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 130 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2002 | 14 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 96 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 801 | 0.010 |
Why?
|